40 completed, 9 terminated, 2 recruiting, 1 active not recruiting. 53 Phase 1, 17 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Completed 40, Terminated 9, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 17 | Completed 14, Terminated 2, Recruiting 1 |
Follow Recurrent Breast Cancer: new trials by email Literature Review of Recurrent Breast Cancer trials Research Report on Recurrent Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer Bortezomib (B), Cisplatin (CDDP) - Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 | Recruiting | Sun Yat-sen University | 20 | 2025-01-01 | 2025-04-02 |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule - Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 154 | 2023-04-13 | 2024-03-12 |
| A Study to Investigate LYL797 in Adults With Solid Tumors LYL797 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 | Terminated | Lyell Immunopharma, Inc. | 57 | 2022-03-29 | 2025-07-01 |
| ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer ONO-4578, letrozole, Palbociclib - Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 46 | 2021-11-09 | 2026-06-05 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer Palbociclib, Avelumab - Triple Negative Breast Cancer, Locally Advanced Breast Cancer | Phase 1 | Active not recruiting | Royal Marsden NHS Foundation Trust | 45 | 2020-08-11 | 2026-08-21 |
| B002 in Patients With HER2-positive Breast Cancer Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002. - Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 1 | Completed | Shanghai Pharmaceuticals Holding Co., Ltd | 23 | 2019-05-28 | 2023-03-24 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer Trastuzumab, NK immunotherapy - Recurrent Breast Cancer | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2016-07-01 | 2019-09-12 |
| Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer Taselisib, Trastuzumab emtansine, Pertuzumab - Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | Nancy Lin, MD | 68 | 2015-04-20 | 2026-09-24 |
| Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Withdrawn | City of Hope Medical Center | 2014-07-01 | 2014-05-30 | |
| BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx PI3K inhibitor BYL719, ado-trastuzumab emtansine, pharmacological study - HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | Northwestern University | 17 | 2014-05-21 | 2020-06-29 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Romidepsin, Abraxane - HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2014-04-01 | 2025-05-16 |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer ganetespib, paclitaxel, trastuzumab - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 9 | 2014-04-01 | 2018-06-14 |
| Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Ruxolitinib, Paclitaxel - Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 20 | 2014-02-01 | 2021-04-21 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer mifepristone, carboplatin, gemcitabine hydrochloride - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | University of Chicago | 31 | 2013-11-01 | 2018-09-11 |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer cisplatin, laboratory biomarker analysis, pharmacological study - Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 11 | 2013-09-01 | 2017-06-27 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis lapatinib ditosylate, everolimus, capecitabine - Central Nervous System Metastases, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 9 | 2013-06-26 | 2019-11-12 |
| BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer PI3K inhibitor BYL719, letrozole, laboratory biomarker analysis - Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 46 | 2013-04-01 | 2026-08-19 |
| Phase I: At-Home Support for Rural Women Using Group Video Calling support group therapy, educational intervention - Depression, Post-traumatic Stress Disorder | Phase 1 | Completed | Stanford University | 34 | 2012-10-01 | 2014-10-17 |
Showing 20 of 53. Sign in to see all of them.
Breast Neoplasms (53) · Breast Neoplasms, Male (27) · Carcinoma, Ovarian Epithelial (13) · Stomach Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (8) · Colonic Neoplasms (8) · Pancreatic Neoplasms (7) · Rectal Neoplasms (7) · Salivary Gland Neoplasms (7) · Prostatic Neoplasms (6) · Carcinoma, Renal Cell (5) · Endometrial Neoplasms (5) · Esophageal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Triple Negative Breast Neoplasms (5)
Breast Diseases (53) · Neoplasms (53) · Neoplasms by Site (53) · Skin Diseases (53) · Skin and Connective Tissue Diseases (53) · Neoplasms by Histologic Type (18) · Carcinoma (16) · Endocrine Gland Neoplasms (16) · Endocrine System Diseases (16) · Neoplasms, Glandular and Epithelial (16) · Urogenital Diseases (16) · Urogenital Neoplasms (16) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15)
Trastuzumab (9) · Paclitaxel (8) · Taxes (7) · Capecitabine (4) · Cyclophosphamide (4) · Cisplatin (3) · Granulocyte-Macrophage Colony-Stimulating Factor (3) · Lapatinib (3) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (3) · Vinorelbine (3) · Vorinostat (3) · sargramostim (3) · Ado-Trastuzumab Emtansine (2) · Albumin-Bound Paclitaxel (2) · Alpelisib (2)
National Cancer Institute (NCI) (18) · University of Washington (6) · City of Hope Medical Center (2) · University of Chicago (2) · Vanderbilt-Ingram Cancer Center (2) · AIDS Malignancy Consortium (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · Fuda Cancer Hospital, Guangzhou (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Klus Pharma Inc. (1) · Lyell Immunopharma, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · NYU Langone Health (1)
United States (46) · China (4) · Canada (2) · Japan (1) · United Kingdom (1)
Lupe Salazar (2) · Mary Disis (2) · Rita Nanda (2) · William Carson (2) · Agustin Garcia (1) · Alicia Okines (1) · Alison Stopeck (1) · Amye Tevaarwerk (1) · Antonius Miller (1) · Beth Overmoyer, MD (1) · Charles Shapiro (1) · Cheryl Koopman (1) · Claudine Isaacs (1) · Cynthia Ma (1) · David Solit (1)
PMID 20357034, PMID 27190628, PMID 28764748, PMID 30542377, PMID 33585999, PMID 35429391, PMID 40187749
P30CA014520 (3), U01CA062491 (3), U01CA076576 (3), P30CA015704 (2), U01CA069856 (2), N01CM62204 (1), P01CA043904 (1), P30CA008748 (1), P30CA013330 (1), P30CA014599 (1), P30CA015083 (1), P30CA023074 (1), P30CA044579 (1), P30CA060553 (1), P30CA076292 (1)